Mira Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MIRA Pharmaceuticals reported significant net losses for 2025, raising going concern doubts, while advancing its drug candidates Ketamir-2, MIRA-55, and SKNY-1 through clinical and preclinical stages.
NASDAQ
MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include the consent of Salberg & Company P.A.
NASDAQ
MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include a policy regarding the recovery of erroneously awarded compensation.
NASDAQ
10-K: MIRA Pharmaceuticals Reports 2024 Results, Highlights Pipeline Progress and Strategic Acquisition
MIRA Pharmaceuticals files its 10-K for the year ended December 31, 2024, detailing financial results, pipeline advancements, and a planned acquisition of SKNY Pharmaceuticals.
NASDAQ
MIRA Pharmaceuticals' 10-K filing outlines its capital structure, governance, and the development status of its neuroscience programs, including Ketamir-2 and MIRA-55.